DK1143994T3 - Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme - Google Patents

Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme

Info

Publication number
DK1143994T3
DK1143994T3 DK00900970T DK00900970T DK1143994T3 DK 1143994 T3 DK1143994 T3 DK 1143994T3 DK 00900970 T DK00900970 T DK 00900970T DK 00900970 T DK00900970 T DK 00900970T DK 1143994 T3 DK1143994 T3 DK 1143994T3
Authority
DK
Denmark
Prior art keywords
auto
apoptosis
medicament
manufacture
treatment
Prior art date
Application number
DK00900970T
Other languages
English (en)
Inventor
Mathieu Hubertus Mari Noteborn
Alexandra Maria Pietersen
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of DK1143994T3 publication Critical patent/DK1143994T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK00900970T 1999-01-11 2000-01-10 Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme DK1143994T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200056 1999-01-11
PCT/NL2000/000013 WO2000041497A2 (en) 1999-01-11 2000-01-10 Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Publications (1)

Publication Number Publication Date
DK1143994T3 true DK1143994T3 (da) 2003-10-20

Family

ID=8239795

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00900970T DK1143994T3 (da) 1999-01-11 2000-01-10 Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme

Country Status (18)

Country Link
US (1) US20050271624A1 (da)
EP (1) EP1143994B1 (da)
JP (1) JP2003500336A (da)
AT (1) ATE244014T1 (da)
AU (1) AU3083500A (da)
CA (1) CA2359392A1 (da)
DE (1) DE60003632T2 (da)
DK (1) DK1143994T3 (da)
EA (1) EA200100770A1 (da)
ES (1) ES2202039T3 (da)
HU (1) HUP0200552A2 (da)
IL (2) IL144228A0 (da)
MX (1) MXPA01006998A (da)
NO (1) NO20013397L (da)
PT (1) PT1143994E (da)
TR (1) TR200102713T2 (da)
WO (1) WO2000041497A2 (da)
ZA (1) ZA200105632B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079222A2 (en) * 2001-03-30 2002-10-10 Leadd B.V. Fusion proteins for specific treatment of cancer and auto-immune diseases
US6924266B2 (en) * 2001-05-25 2005-08-02 Nymox Corporation NTP-peptides and method for removal of tumors
PL207588B1 (pl) * 2001-07-19 2011-01-31 Nymox Corp Peptyd NTP, środek zawierający ten peptyd i zastosowanie tego peptydu
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
NZ309171A (en) * 1995-06-07 2000-04-28 Leadd Bv use of apoptin as an antitumour agent which specifically kills tumour and not normal cells
DE19704979A1 (de) * 1996-02-07 1997-08-14 Max Delbrueck Centrum Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen
JP2001516210A (ja) * 1997-02-28 2001-09-25 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 遺伝子治療による炎症細胞の自己調節されたアポトーシス
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトFasヒト化抗体
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody

Also Published As

Publication number Publication date
WO2000041497A2 (en) 2000-07-20
JP2003500336A (ja) 2003-01-07
HUP0200552A2 (en) 2002-06-29
DE60003632D1 (de) 2003-08-07
EA200100770A1 (ru) 2002-02-28
PT1143994E (pt) 2003-11-28
NO20013397L (no) 2001-09-11
ZA200105632B (en) 2002-10-09
TR200102713T2 (tr) 2002-05-21
ATE244014T1 (de) 2003-07-15
IL144228A0 (en) 2002-05-23
EP1143994B1 (en) 2003-07-02
ES2202039T3 (es) 2004-04-01
EP1143994A2 (en) 2001-10-17
MXPA01006998A (es) 2002-05-06
AU3083500A (en) 2000-08-01
DE60003632T2 (de) 2004-04-15
IL144228A (en) 2009-06-15
NO20013397D0 (no) 2001-07-09
CA2359392A1 (en) 2000-07-20
US20050271624A1 (en) 2005-12-08
WO2000041497A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
TNSN08064A1 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
MX2009002816A (es) Proteinas de fusion de albumina.
FI963101A (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
WO2003060071A3 (en) Albumin fusion proteins
WO2001079443A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
AU2002257162A1 (en) Humanized antibodies
EP1385545A4 (en) HUMANIZED ANTIBODIES
CY1108489T1 (el) Παραγωγη τετρασθενων αντισωματων
HUP0300369A2 (hu) Többértékű antitestek és alkalmazásuk
NO20000450L (no) Substituerte fenylalaninforbindelser som inhiberer leukocytt- adhesjon mediert av VLA-4
WO2001064889A3 (en) Tnf-alpha variants for the treatment of tnf-alpha related disorders
MX2009012948A (es) Nuevas indicaciones para la terapia anti-il-1-beta.
DK1143994T3 (da) Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme
NO20076663L (no) Immunoglobuliner
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
EP1475441A3 (fr) Acides nucléiques et polypeptides spécifiques des souches pathogènes du genre Neisseria
DE60038955D1 (de) AN DER OBERFLÄCHE VON KARZINOMZELLEN LOKALISIERTES COLLIGIN/HsP47
DK1196188T3 (da) VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2006048657A3 (en) Fras related protein
WO2002063013A3 (en) Human acid phosphatase gene